Basics CorMedix Inc. Cormedix Inc is a commercial-stage biopharmaceutical company. It focuses on development and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. IPO Date: May 13, 2010 Sector: Healthcare Industry: Biotech Market Cap: $832.01M Activated in VL: True Average Daily Range Avg Daily Range: $0.14 | 4.09% Avg Daily Range (30 D): $0.27 | 2.52% Avg Daily Range (90 D): $0.31 | 2.66% Institutional Daily Volume Avg Daily Volume: .6M Avg Daily Volume (30 D): 2.57M Avg Daily Volume (90 D): 3.03M Trade Size Avg Trade Size (Sh.): 202 Avg Trade Size (Sh.) (30 D): 115 Avg Trade Size (Sh.) (90 D): 125 Institutional Trades Total Inst.Trades: 769 Avg Inst. Trade: $1.49M Avg Inst. Trade (30 D): $1.37M Avg Inst. Trade (90 D): $1.53M Avg Inst. Trade Volume: .14M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $1.83M Avg Closing Trade (30 D): $1.82M Avg Closing Trade (90 D): $2.1M Avg Closing Volume: 186.24K     News Nov 21, 2025 @ 2:00 PM American Kidney Fund Hosts Third Patient Access In... Source: Lavarne A. Burton Nov 12, 2025 @ 4:00 PM Strong Earnings and Biotech Resilience Define the ... Source: Na Sep 29, 2025 @ 12:30 PM CorMedix Announces Completion of Enrollment in Pha... Source: Globe Newswire Sep 2, 2025 @ 11:30 AM CorMedix Completes Acquisition of Melinta Therapeu... Source: Globe Newswire Dec 10, 2024 @ 7:45 AM Closed System Transfer Device Market Size Poised t... Source: Polaris Market Research Financials   TTM Q3 2025 Q2 2025 Basic EPS $2.26 $1.42 $.29 Diluted EPS $2.08 $1.26 $.28 Revenue $ 214.3M $ 104.28M $ 39.74M Gross Profit $ 198.47M $ 93.08M $ 37.87M Net Income / Loss $ 162.5M $ 108.56M $ 19.83M Operating Income / Loss $ 103.95M $ 51.35M $ 19.54M Cost of Revenue $ 12.2M $ 7.57M $ 1.86M Net Cash Flow $ 14.09M $ -109.93M $ 93.02M PE Ratio 5.08     Splits Mar 26, 2019:   1:5